Latest News

Researchers highlight the critical link between school vaccination rates and measles outbreaks, urging targeted public health strategies to combat misinformation and improve MMR coverage.

Discover groundbreaking FDA approvals for innovative treatments, including semaglutide for liver health and bumetanide nasal spray for heart failure.

Explore recent FDA-approved drugs from September 2025.

Combining tramadol with CYP2D6-inhibiting antidepressants raises seizure risk in older adults, highlighting the need for careful medication management.

Repetitive DNA mimics pathogens, influencing cancer immunity and immunotherapy.

Research reveals that poor glycemic control in adolescents with type 1 diabetes significantly increases the risk of developing neuropathy in adulthood.

Tramadol provides only limited pain relief while carrying a significant risk of serious adverse effects.

Hallucinatory affects associated with psychedelic drugs and Lewy body diseases may have some commonalities.

Many factors lead to policy change and market viability, but none more than perceived need and desire to receive a service.

As one of the most prescribed medications worldwide, proton pump inhibitor use could serve as a bulwark against severe outcomes in hospitalized adults with COVID-19.

Niraparib combined with standard therapy significantly improves progression-free survival in men with HRR-deficient metastatic castration-sensitive prostate cancer.

Researchers explore continuous glucose monitors (CGMs) for early detection of insulin issues, aiming to prevent diabetes progression and improve screening methods.

Cemiplimab's approval is supported by findings from the C-POST clinical trial.

New research confirms that calcium supplements do not increase dementia risk in older women, supporting their use for bone health without cognitive concerns.

Medicaid expansion enhances 5-year cancer survival rates in rural and high-poverty areas, highlighting the importance of financial support for better health outcomes.

This is the first pediatric FDA approval for golimumab, according to the manufacturer.

Aumolertinib and osimertinib show similar efficacy and safety when treating patients with EGFR-mutant non–small cell lung cancer (NSCLC), providing valuable insights for treatment optimization.

A retrospective analysis found no associations between lipid parameters and the success of blood stem cell mobilization in a cohort of healthy donors.

Frail patients with multiple myeloma (MM) can safely reduce dexamethasone use, enhancing treatment outcomes without increasing infection risks.

Cagrilintide shows significant weight loss in adults with obesity, marking a breakthrough in obesity treatment with promising phase 3 trial results.